Glasgow, UK based - ScreenIn3D, a partner of AMSBIO, reports on the accolades it has received following the recent launch of its novel microfluidic cancer screening service.Combining the latest advances in microfluidics and 3D culture - the service uses an optimised screening platform targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions.At the recent Miptec conference in Basle, Switzerland - ScreenIn3D was one of 60 global organisations invited to showcase its cutting-edge life science technologies for research, science…
Oxford, UK, 08 October 2018: Aigenpulse Ltd., (Aigenpulse), a company at the forefront of employing data technologies and advanced machine learning to accelerate drug discovery, today announced the appointment of Dr Satnam Surae as Chief Product Officer. The appointment continues the rapid expansion of the company, which has grown four-fold in the last year and is the first in a series of senior appointments.
Dr Surae was the first employee at Aigenpulse when he joined in October 2016, and most recently held the role of Lead Computational Biologist. He has extensive experience in…
Research Triangle Park, NC and Cambridge, UK, September 24, 2018 -- Inivata, a leader in liquid biopsy today announces that results from its US multi-centre prospective validation study of its InVisionFirst-Lung liquid biopsy test will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).The data will be presented by the lead author of the study, Dr Ramaswamy Govindan, Professor of Medicine, at the Washington University School of Medicine, on September 25, 13.30-15.00: Prospective clinical validation of the…
21 September 2018
Axol, the rapidly growing specialist in human cell culture, is delighted to announce it has opened a new operational hub in the US. The site which opened for business in Massachusetts on Friday 21st September will help support Axol’s customer base in the United States and Canada.
Commenting on the move, Rob Treanor, Axol’s Head of Supply said: “Our new facility allows us to greatly enhance the service level and support we provide for our US customers. By investing in a local presence in the US, we take a step closer to achieving our aspiration of being the leading…
20 September 2018
Cambridge, UK, 20th September 2018 / Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018. Dr Perrior has held the position of Director of Research and Chief Scientific Officer at Domainex since 2005. The company has grown significantly during his tenure, delivering numerous development candidates across several therapeutic areas. Following his education at the University of Cambridge, Dr Perrior undertook academic research at…
19 September 2018
AMSBIO announce the launch of a new range of circulating tumor DNA (ctDNA) Reference Standards for cancer disease management research.A critical goal in cancer disease management is early detection. When detected early, cancer progression can be arrested using techniques such as targeted therapy, chemotherapy and surgery thereby increasing the chances of survival and a higher quality of life. Liquid biopsy offers the promise of providing a quick, non-invasive and cost-effective alternative to surgical biopsies, allowing tumor analysis through a simple blood sample. Traces of…
17 September 2018
Science Exchange, the leading marketplace for outsourced R&D™, announced today that it has become a Corporate Partner of One Nucleus, the membership organization for life science and healthcare companies. This exclusive partnership will give One Nucleus members immediate access to thousands of CROs, CMOs, academic institutes, core labs and a global community of scientists from the world’s top R&D organizations.Based in Cambridge, England, One Nucleus supports institutions, companies, and individuals in its region by connecting them to a vast network of UK-wide and…
17 September 2018
Cambridge and Ongar, UK, 17th September 2018 / Sciad Newswire / A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry. The authors describe the identification of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent HCV activity. These compounds also provide starting points for drug discovery programmes in several other major diseases…
17 September 2018
Cambridge, UK, September 14 2018: Owlstone Medical Ltd (or the “Company”), a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
Dr Richards is a serial entrepreneur and business angel with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. His early career spans positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive…
17 September 2018
Cambridge, UK, 17 September 2018: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows.Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, isolation and clone verification. Its…